False about RANK – Ligand is :
**Core Concept**
The RANK-Ligand (RANKL) system plays a crucial role in osteoclast differentiation and activation, leading to bone resorption. RANKL is a critical factor in the pathogenesis of bone diseases such as osteoporosis and bone metastasis. It interacts with its receptor, RANK, on the surface of osteoclasts, promoting their formation and activity.
**Why the Correct Answer is Right**
RANKL binds to its receptor RANK on the surface of osteoclasts, osteoclast precursors, and osteoblasts. This binding leads to the activation of osteoclasts, resulting in increased bone resorption. The RANKL-RANK interaction is essential for the development and maintenance of bone homeostasis. RANKL is also involved in the regulation of immune cell function and has been implicated in various inflammatory and autoimmune diseases.
**Why Each Wrong Option is Incorrect**
**Option A:** RANKL is a cytokine produced by osteoblasts.
* This is incorrect because RANKL is not a cytokine but a transmembrane protein that can be cleaved to form a soluble form.
**Option B:** RANKL is involved in the regulation of osteoblast differentiation.
* This is incorrect because RANKL primarily regulates osteoclast differentiation and activation, rather than osteoblast differentiation.
**Option C:** RANKL is expressed by T cells.
* This is incorrect because RANKL is primarily expressed by osteoblasts, stromal cells, and activated T cells, but not by all T cells.
**Clinical Pearl / High-Yield Fact**
RANKL inhibitors, such as denosumab, are effective in treating bone metastasis and osteoporosis by blocking the RANKL-RANK interaction, thereby reducing bone resorption.
**Correct Answer:** None